Matrixx Decision Raises More Disclosure Questions – Law Professor
This article was originally published in The Tan Sheet
Executive Summary
The Supreme Court's decision in the lawsuit alleging Matrixx Initiatives fraudulently withheld adverse event reports from investors provides little guidance for pharmaceutical and dietary supplement firms on disclosing adverse events, an expert says.
You may also be interested in...
FDLI Conference In Brief
Law professor dubs Zicam AER case one to watch in 2012; Cargill draws legal line between customers’ food and supplement products.
FDLI Conference In Brief
Law professor dubs Zicam AER case one to watch in 2012; Cargill draws legal line between customers’ food and supplement products.
Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden
The Supreme Court's decision in a complaint shareholders brought against Matrixx Initiatives lowers the threshold for when firms need to disclose information, but also aims to prevent an "avalanche of trivial information."